• 

 

 

Prof. Kim Eui-tae from the Department of Microbiology at JNU College of Medicine has been selected as the lead implementer for the "2024 Project to Accelerate Domestic Development of Gene Delivery Systems in Korea," a national initiative supported by the Ministry of Health and Welfare.

Established in 2023, this project is part of the government’s 3rd Basic Plan for the Promotion of Health and Medical Technology. Its goal is to discover and support research and development in renewable medical innovation technologies, specifically aimed at developing advanced gene therapy drugs.

Leveraging his extensive experience in viral gene carrier development and existing research, Prof. Kim aims to create a high-performance platform that addresses the limitations of current gene carriers. His objective is to advance to the preclinical stage by producing gene therapy drugs targeting rare genetic diseases.

Since 2022, Prof. Kim has been working on the "Regenerative Medical Clinical Research Foundation Project," supported by the Ministry of Health and Welfare. This project has focused on discovering viral materials for gene therapy drug production and developing related production processes.

With this follow-up research project, Prof. Kim intends to expedite the development of next-generation gene therapy drugs. He stated, “Through this research project, we will concentrate our efforts on providing effective and economical high-tech biopharmaceuticals to patients with rare genetic diseases.”

With this follow-up research project, Prof. Kim intends to expedite the development of next-generation gene therapy drugs. He stated, “Through this research project, we will concentrate our efforts on providing effective and economical high-tech biopharmaceuticals to patients with rare genetic diseases.”

The total expenses for the project will be KRW 4.35 billion, including KRW 3.8 billion from national funds and KRW 5 million from other sources, allocated over 3 years and 6 months.

Organized by Prof. Kim Eui-tae, the project also involves collaboration with Professor Kim Kyung-dong from the Department of System Biotechnology at Chung-Ang University. In addition, bio companies such as Feroka Co., Ltd. and CellBion Co., Ltd., as well as the K-Bio CMO Center, will form a consortium to participate in the research project.